Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181

Oeckl, Patrick; Wagemann, Olivia; Halbgebauer, Steffen; Anderl-Straub, Sarah; Nuebling, Georg; Prix, Catharina; Loosli, Sandra V.; Wlasich, Elisabeth; Danek, Adrian; Steinacker, Petra; Ludolph, Albert C.; Levin, Johannes und Otto, Markus (2022): Serum Beta-Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181. In: Annals of Neurology, Bd. 92, Nr. 1: S. 6-10

Abstract

This exploratory case-control study investigates the synaptic marker beta-synuclein in serum and plasma pTau181 in adults with Down syndrome (DS) with (sDS, n = 14) and without (aDS, n = 47) clinical symptoms of Alzheimer disease (AD) as well as euploid controls (n = 23). Beta-synuclein was higher in aDS and more pronounced in sDS (p < 0.0001), whereas pTau181 was only higher in sDS (p < 0.0001). Both markers showed good discriminatory power (area under the curve > 0.90) to distinguish symptomatic from asymptomatic AD. The data indicate that synaptic alterations belong to the earliest AD-associated events in DS and highlight the value of serum beta-synuclein as a potential early marker of AD. ANN NEUROL 2022

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin ; Medizin > Munich Cluster for Systems Neurology (SyNergy)
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0364-5134
• Sprache: Englisch
• DFG: Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198